Use of mGluR5 antagonists for the treatment of gerd
US7964609B2 · kind B2 · utility
0Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2003 |
| Grant date | Jun 21, 2011 |
| Priority date | — |
| Expiry date | Aug 24, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.